A phase II trial of combined weekly bortezomib and tositumomab I-131 in patients with relapsed or refractory follicular non-Hodg

Trial Profile

A phase II trial of combined weekly bortezomib and tositumomab I-131 in patients with relapsed or refractory follicular non-Hodg

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2008

At a glance

  • Drugs Bortezomib; Iodine-131 tositumomab
  • Indications Follicular lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Jan 2008 The expected completion date for this trial is now 1 May 2008.
    • 25 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top